By Nicholas G. Miller
Zimmer Biomet now expects to buy back up to $1 billion of its stock during the fiscal year, up $250 million from its previous expectation.
The buybacks will be made under the company's $1.5 billion share repurchase authorization, which it hasn't modified.
Write to Nicholas G. Miller at nicholas.miller@wsj.com.
(END) Dow Jones Newswires
May 12, 2026 07:40 ET (11:40 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.